Rick E. Winningham - 20 Feb 2026 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Brett A Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
20 Feb 2026
Net transactions value
-$1,474,008
Form type
4
Filing time
24 Feb 2026, 19:43:51 UTC
Previous filing
21 Nov 2025
Next filing
03 Apr 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Rick E. Winningham filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 24 Feb 2026."

Quick Takeaways

  • This page summarizes Rick E. Winningham's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 24 Feb 2026, 19:43.

What Changed

  • Previous filing in this sequence was filed on 21 Nov 2025.
  • Current net transaction value: -$1,474,008.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Winningham Rick E CHIEF EXECUTIVE OFFICER, Director C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO /s/ Brett A Grimaud, Attorney-in-Fact 24 Feb 2026 0001302443

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Tax liability $1,474,008 -74,975 -4.5% $19.66 1,576,094 20 Feb 2026 Direct F1
holding TBPH Ordinary Shares 23,400 20 Feb 2026 As Custodian
holding TBPH Ordinary Shares 92,567 20 Feb 2026 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

Sponsored